To determine Minimum Inhibitory Concentration (MIC) of Cefixime in Mahacef® Tablet 200mg and API Cefixime trihydrate compacted IP (API)

Minimum Inhibitory Concentration (MIC) of Cefixime

Abstract

Background: Antibiotic resistance is rising to dangerously high levels globally. New resistance mechanisms are emerging and spreading, thereby threatening our ability to treat common infectious diseases. In places where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. This study endeavours to determine minimum inhibitory concentration (MIC) of Mahacef 200mg Tablet and Cefixime Trihydrate API, both supplied by Mankind Pharma Limited. Methodology: Antibacterial activity of Cefixime on Salmonella enterica subsp. enterica serover Typhimurium was determined by Agar Dilution Method with Mueller Hinton Agar. Available strain of Salmonella enterica subsp. enterica serover Typhimurium (ATCC 14028) was used with Inoculum size was approximately 1000 cfu / plate. Dilutions were prepared in Phosphate buffer (pH 7.0, 0.1 mol/L) for Mahacef 200 mg Tablet and Cefixime Trihydrate API, and used for the study. Results: Findings of this study demonstrate that both Mahacef 200mg Tablet and Cefixime Trihydrate API have shown excellent antibacterial activity in vitro. MICs for the drug product as well as for the drug substance (API) are found to be 0.1 g/mL against Salmonella enterica subsp. enterica serover Typhimurium. Conclusion: Mahacef 200mg andCefixime Trihydrate API clearly establish support for its antimicrobial effectiveness and therefore, support values determined MIC for the viewpoint of medical fraternity that Cefixime is effective for management of typhoid fever.